From GlobeNewswire: 2025-03-12 20:33:00

Anteris Technologies Global Corp. reported financial results for 2024, raising $88.8m through a successful U.S. IPO. They’re preparing to initiate the DurAVR® THV Pivotal Trial, with positive patient data supporting the IDE submission to the FDA. The company concluded 2024 with a strong cash position of $70.5m.

Anteris made significant progress in 2024 towards obtaining FDA approval for the DurAVR® THV Pivotal Trial, including multiple pre-submission meetings and key preparatory activities. Additionally, the company expanded clinical experience with successful cases in the EU-EFS in Denmark, aiming to build awareness of the DurAVR® THV system.

Throughout 2024, Anteris attended major medical conferences to promote the DurAVR® THV system to clinicians. Data presented included US-EFS results, ViV data, and a CMR imaging study. Manufacturing was scaled up to support the Pivotal Trial, with design optimizations to improve procedure efficiency and lower costs.

The DurAVR® THV Pivotal Trial is set to be a head-to-head TAVR registration trial, enrolling up to 1,200 patients across the U.S. and other key markets. The trial aims to establish non-inferiority of the DurAVR® THV compared to existing therapies, with 86 patients already implanted with promising results.

Anteris reported $2.7 million in net sales for 2024, driven by tissue product sales. Operating expenses, including R&D for the Pivotal Trial, led to a net loss of $76.0 million. The company’s financial information is detailed in its Form 10-K filing, including management discussion and risks.

In 2024, Anteris entered a $25.0 million convertible note facility with Obsidian and completed a $79.6 million U.S. IPO. The IPO underwriters exercised an option to purchase additional shares, raising an additional $0.4 million. Anteris is focused on designing, developing, and commercializing medical devices to restore healthy heart function.



Read more at GlobeNewswire:: Anteris Reports 2024 Financial Results and Provides